Education
About Us
Working with TipRanks
Follow Us
Karyopharm Therapeutics (KPTI)
NASDAQ:KPTI
Earnings Data
Report Date
Jul 31, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-4.11Last Year’s EPS
-3Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 12, 2025
|% Change Since: -27.80%
|Next Earnings Date:Jul 31, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in clinical trials and potential market opportunities, particularly in myelofibrosis, but was tempered by financial challenges related to product returns and cash runway concerns. The data on selinexor is promising, but the financials indicate areas of concern that need addressing.Company Guidance
During Karyopharm Therapeutics' First Quarter 2025 Financial Results Conference Call, the company provided several updates on its ongoing projects and financial guidance. They announced that the Phase 3 SENTRY trial in JAKi-naïve myelofibrosis patients has successfully passed its futility analysis and continues as planned, with approximately 80% of the targeted 350 patients enrolled, expecting to complete enrollment by June-July 2025. The company highlighted the potential of selinexor in combination with ruxolitinib to significantly improve patient outcomes in myelofibrosis, with a peak revenue potential of approximately $1 billion in the U.S. alone. For the first quarter of 2025, Karyopharm reported total revenue of $30 million, including U.S. XPOVIO net product revenue of $21.1 million, impacted by a $5 million increase in product return reserves. Despite this, they maintain a total revenue guidance of $140 million to $155 million for the full year 2025, projecting to be at the lower end of this range. The company also noted progress in their endometrial cancer and multiple myeloma trials, with significant commercial opportunities on the horizon.Phase 3 SENTRY Trial Progress
The Phase 3 SENTRY trial in JAKi-naïve myelofibrosis patients has passed its prespecified futility analysis and continues as planned without modifications. Enrollment is at approximately 80% of the target, with completion expected in the June-July timeframe.
Encouraging Selinexor Data
New clinical data shows selinexor may have an impact across key hallmarks of myelofibrosis, with more than double the SVR35 rate compared to ruxolitinib alone and meaningful symptom improvement.
Myelofibrosis Commercial Opportunity
If approved, selinexor in myelofibrosis has a peak revenue potential of up to $1 billion in the U.S. alone, with expected rapid commercial uptake.
Royalty Revenue Growth
Royalty revenue increased 57% to $1.7 million in Q1 2025 compared to Q1 2024, reflecting increasing global demand for XPOVIO and NEXPOVIO.
KPTI Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
KPTI Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 12, 2025 | $6.15 | $4.92 | -20.00% |
Feb 19, 2025 | $9.45 | $9.00 | -4.76% |
Nov 05, 2024 | $14.00 | $12.68 | -9.43% |
Aug 06, 2024 | $13.06 | $12.60 | -3.52% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Karyopharm Therapeutics (KPTI) report earnings?
Karyopharm Therapeutics (KPTI) is schdueled to report earning on Jul 31, 2025, TBA Not Confirmed.
What is Karyopharm Therapeutics (KPTI) earnings time?
Karyopharm Therapeutics (KPTI) earnings time is at Jul 31, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is KPTI EPS forecast?
KPTI EPS forecast for the fiscal quarter 2025 (Q2) is -4.11.